儿童及青少年癌症与儿童造血干细胞移植受者艰难梭菌感染管理指南
该指南由国际多学科专家组制定,采用GRADE方法,针对癌症儿童及青少年和儿童造血干细胞移植受者艰难梭菌感染的预防与治疗提出推荐。推荐非重症CDI初始治疗口服甲硝唑或口服万古霉素,重症CDI初始治疗口服万古霉素;复发性CDI可考虑非达霉素;不建议常规使用益生菌预防CDI,不建议常规使用单克隆抗体和益生菌治疗CDI,强烈推荐不使用粪菌移植。
要点
- 非重症CDI初始治疗:强烈推荐口服甲硝唑或口服万古霉素。
- 重症CDI初始治疗:强烈推荐口服万古霉素。
- 复发性CDI可考虑非达霉素;强烈推荐不使用粪菌移植。
核心结论
- 本指南针对癌症儿童及青少年和儿童HSCT受者CDI的预防与治疗提出推荐。
- 未来研究应包括涉及癌症儿童和儿童HSCT患者的随机对照试验。
研究设计与样本
- 国际多学科专家组(含儿科肿瘤学、感染性疾病专家及患者代表)制定。
- 对任何人群预防或治疗CDI的随机对照试验进行系统评价,并考虑证据对癌症儿童和儿童HSCT患者的直接性。
- 采用GRADE方法生成推荐。
主要发现
- 专家组强烈推荐口服甲硝唑或口服万古霉素用于非重症CDI的初始治疗。
- 专家组强烈推荐口服万古霉素用于重症CDI的初始治疗。
- 复发性CDI可考虑非达霉素。
- 专家组建议不常规使用益生菌预防CDI。
- 专家组建议不常规使用单克隆抗体和益生菌治疗CDI。
关键数值与推荐
- 非重症CDI初始治疗:强烈推荐口服甲硝唑或口服万古霉素。
- 重症CDI初始治疗:强烈推荐口服万古霉素。
- 复发性CDI:可考虑非达霉素。
- 预防CDI:建议(弱推荐)不常规使用益生菌。
- 治疗CDI:建议(弱推荐)不常规使用单克隆抗体和益生菌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出存在关键知识缺口,并提出了未来研究方向。
- 原文结论提出未来研究应包括涉及癌症儿童和儿童HSCT患者的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this work was to develop a clinical practice guideline for the prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation (HSCT) patients. METHODS: An international multidisciplinary panel of experts in pediatric oncology and infectious diseases with patient advocate representation was convened. We performed systematic reviews of randomized controlled trials for the prevention or treatment of CDI in any population and considered the directness of the evidence to children with cancer and pediatric HSCT patients. We used the Grading of Recommendations Assessment, Development, and Evaluation approach to generate recommendations. RESULTS: The panel made strong recommendations to administer either oral metronidazole or oral vancomycin for the initial treatment of nonsevere CDI and oral vancomycin for the initial treatment of severe CDI. Fidaxomicin may be considered in the setting of recurrent CDI. The panel suggested that probiotics not be routinely used for the prevention of CDI, and that monoclonal antibodies and probiotics not be routinely used for the treatment of CDI. A strong recommendation to not use fecal microbiota transplantation was made in this population. We identified key knowledge gaps and suggested directions for future research. CONCLUSION: We present a guideline for the prevention and treatment of CDI in children and adolescents with cancer and pediatric HSCT patients. Future research should include randomized controlled trials that involve children with cancer and pediatric HSCT patients to improve the management of CDI in this population.
引用
- Diorio C, Robinson PD, Ammann RA, et al. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol. 2018. PMID: 30216124. doi:10.1200/JCO.18.00407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。